Skip to content
Medium Biosciences logo

Medium Biosciences

Medium Biosciences is a YC Summer 2021 (S21) company. Based in San Francisco, CA, USA. Team of 6.

  • AI-powered Drug Discovery
  • Machine Learning
  • Biotech
  • AI

About Medium Biosciences

GPAgent's own fund-neutral profile, written from public information. Updated Oct 4, 2026.

Summary

Medium Biosciences designs and delivers custom affinity reagents, using AI and protein engineering to produce experimentally validated molecular tools for research teams and diagnostic developers. It replaces the slow, generalist process of sourcing or developing binding proteins in-house, delivering validated reagents tailored to a specific target and application in weeks rather than months.

Business model

Per-project fee for custom affinity reagent design and delivery.

Go-to-market

Customers, spanning academic labs and industry diagnostics teams, initiate projects by describing their target molecule, after which Medium Biosciences scopes and executes the custom reagent build on demand.

From the Y Combinator listing

How Medium Biosciences describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

AI-designed Protein Therapeutics

We develop AI models & new assays to create functional, therapeutic proteins.

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Location
San Francisco, CA, USA
Team size
6
Status
Active
Stage
Early

Founders (2)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works